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Clinical PerspectiveWhat Is New?Baseline orthostatic hypotension (OH), assessed using beat‐to‐beat blood pressure response to stand, is associated with a decline in global cognitive performance at 4‐year follow‐up.This association is most evident in the middle‐age group (50--64 years), who demonstrated a decline in cognition at follow‐up.Participants with both OH and hypertension demonstrate the most dramatic decline in cognition.What Are the Clinical Implications?OH in midlife (50--64 years) is associated with a decline in global cognitive performance at 4‐year follow‐up, and further studies are required to assess whether intervention in OH could prevent or slow cognitive decline.Recognition of co‐existent OH in individuals with hypertension is important, given evidence of a decline in global cognition in these individuals.

Introduction {#jah33505-sec-0008}
============

Orthostatic hypotension (OH) is traditionally defined as a sustained reduction in systolic blood pressure (BP) of at least 20 mm Hg or diastolic BP of 10 mm Hg within 3 minutes of standing.[1](#jah33505-bib-0001){ref-type="ref"} It can occur within 30 seconds of stand (initial OH), between 30 seconds and 3 minutes of stand (classical OH), or after 3 minutes of stand (delayed OH).[2](#jah33505-bib-0002){ref-type="ref"} The prevalence of OH increases with age, and previous analysis of the TILDA (The Irish Longitudinal Study on Ageing) data has found a prevalence of impaired BP stabilization on stand of 15.6% of participants, rising from 14.3% of men and 16.9% of women aged 50 to 59 years, to 43.4% of men and 39.9% of women over the age of 80 years.[3](#jah33505-bib-0003){ref-type="ref"} Several mechanisms are responsible for impairment in BP control, including impaired baroreflex sensitivity, abnormal neurohumeral regulation, impaired thirst, dehydration, and impaired venomotor tone.[4](#jah33505-bib-0004){ref-type="ref"}, [5](#jah33505-bib-0005){ref-type="ref"}

Recently, more refined methods of measurement of BP behavior during orthostasis using technologies that measure beat‐to‐beat BP have demonstrated that failure to stabilize BP during early stages of stand are associated with falls and syncope,[2](#jah33505-bib-0002){ref-type="ref"} depression,[6](#jah33505-bib-0006){ref-type="ref"} and with cognitive impairment.[7](#jah33505-bib-0007){ref-type="ref"}

Aging may be associated with a decline in cognitive abilities such as memory, attention, processing speed, language, and visuospatial and executive function.[8](#jah33505-bib-0008){ref-type="ref"} The prevalence of age‐associated cognitive decline is 15% in persons over 60 years.[9](#jah33505-bib-0009){ref-type="ref"} Mild cognitive impairment is a decline in cognition that is worse than normative data for a set age and education level, but does not meet the criteria for the diagnosis of dementia.[10](#jah33505-bib-0010){ref-type="ref"} Prevalence data for mild cognitive impairment vary greatly, with the prevalence of mild cognitive impairment having been reported as up to 42% of individuals.[9](#jah33505-bib-0009){ref-type="ref"} The main differentiating criterion for dementia is the existence of functional impairment.[11](#jah33505-bib-0011){ref-type="ref"} The brain is highly metabolically active, and precise regulation of cerebral blood flow (cerebral autoregulation) is required to maintain a constant nutrient and oxygen supply to the brain.[12](#jah33505-bib-0012){ref-type="ref"} There is evidence that cerebral blood flow can be compromised in OH,[13](#jah33505-bib-0013){ref-type="ref"}, [14](#jah33505-bib-0014){ref-type="ref"} and it has been postulated that OH can increase the risk of cognitive impairment through alterations in cerebral blood flow. Several cross‐sectional studies have shown an association between OH and cognitive decline,[7](#jah33505-bib-0007){ref-type="ref"}, [15](#jah33505-bib-0015){ref-type="ref"}, [16](#jah33505-bib-0016){ref-type="ref"}, [17](#jah33505-bib-0017){ref-type="ref"}, [18](#jah33505-bib-0018){ref-type="ref"} including cross‐sectional analysis of the first wave of the TILDA data set.[7](#jah33505-bib-0007){ref-type="ref"}, [15](#jah33505-bib-0015){ref-type="ref"} A number of longitudinal studies have investigated directionality of this association; however, in contrast to most cross‐sectional studies, a majority did not find an association.[19](#jah33505-bib-0019){ref-type="ref"}, [20](#jah33505-bib-0020){ref-type="ref"}, [21](#jah33505-bib-0021){ref-type="ref"}, [22](#jah33505-bib-0022){ref-type="ref"}, [23](#jah33505-bib-0023){ref-type="ref"} BP measurement in the majority of these studies was assessed using oscillometric lying and standing BP, a more crude method of BP measurement than beat‐to‐beat measurement.[19](#jah33505-bib-0019){ref-type="ref"}, [20](#jah33505-bib-0020){ref-type="ref"}, [22](#jah33505-bib-0022){ref-type="ref"} The TILDA data set provides a unique opportunity to study the effect of more dynamic shifts in orthostatic BP, as measured by beat‐to‐beat BP, on cognitive function.

The aim of this study is to assess whether baseline OH at 40 and 110 seconds after stand is associated with a decline in cognitive scores at 4‐year follow‐up in a community‐dwelling sample over the age of 50 years.

Methods {#jah33505-sec-0009}
=======

Study Sample {#jah33505-sec-0010}
------------

Data from TILDA (The Irish Longitudinal Study on Ageing) were used. The anonymized TILDA data set is available to researchers who meet the criteria for access from the Irish Science Data Archive at University College Dublin and the Interuniversity Consortium for Political and Social Research at the University of Michigan, and TILDA also considers applications for privileged access to the data set through an onsite "hot desk" facility (visit <http://www.tilda.ie> for further information).

TILDA is a large prospective cohort study comprising community‐dwelling adults over the age of 50 years in the Republic of Ireland, repeatedly assessed at 2‐year intervals. At wave 1, a nationally representative sample was drawn from a listing of all residential addresses in the Republic of Ireland using the RANSAM sampling procedure,[24](#jah33505-bib-0024){ref-type="ref"} with a response rate of 62%. Details of the sampling method have been published elsewhere.[24](#jah33505-bib-0024){ref-type="ref"} The TILDA study comprised (1) a computer‐aided personal interview (CAPI), carried out by trained interviewers in participants' homes; (2) a self‐completion questionnaire; and (3) a health assessment carried out by trained research nurses. All participants who completed the CAPI were invited to attend 1 of 2 health centers for health assessment. As part of a comprehensive health assessment, participants completed a cardiovascular assessment, which included beat‐to‐beat measurements of BP during active stand and the Montreal Cognitive Assessment (MOCA). This study included all participants who completed both the CAPI and health assessment at wave 1 (2009--2011) and had adequate active stand data for analysis of orthostatic BP behavior, as well as completing both the CAPI and MOCA at wave 3 (4‐year follow‐up period). Participants who had a self‐reported doctor\'s diagnosis of dementia, a MOCA score \<20, Parkinson\'s disease, or stroke at wave 1 or a subsequent diagnosis of Parkinson\'s or stroke between waves 1 and 3, were excluded from the analyses.

Ethical approval for TILDA was obtained from the Trinity College Research Ethics committee, and participants provided written informed consent.

BP Measurement {#jah33505-sec-0011}
--------------

Participants who attended the health center underwent active stand, which noninvasively measures beat‐to‐beat BP response to orthostasis using digital photoplethysmography (Finometer MIDI device; Finapres Medical Systems). Participants underwent assessment of BP response to stand, following 10 minutes of supine rest. Baseline BP was measured as the mean value between 60 and 30 seconds before stand, during the supine rest period. BP response to stand was measured up to 110 seconds post stand. BP was estimated at 10‐second intervals, using 5‐second moving averages around each point. Two measurements of OH were analyzed. OH at 40 seconds (OH40) was defined as a sustained drop of ≥20 mm Hg systolic BP (SBP) or ≥10 mm Hg diastolic BP (DBP) at each time point up to 40 seconds post stand. Previous analysis of the TILDA data has demonstrated that while there is a wide range of BP response patterns to active stand, the majority of participants stabilize their BP by 30 seconds,[3](#jah33505-bib-0003){ref-type="ref"} and so we chose the 40 seconds cut‐off to represent the participants who fail to stabilize their BP by this time point. A subset of these participants with OH at 110 seconds (OH110) was also analyzed and defined as a sustained drop of ≥20 mm Hg SBP or ≥10 mm Hg DBP at each time point up to 110 seconds post stand. As BP was estimated at intervals using 5‐second moving averages, the point at 120 seconds (duration of the stand at wave 1) in most individuals would include edge effects and so we chose the 110‐seconds point to assess a subset of the participants with OH that represent the "worst" group---that is, those who do not stabilize their BP throughout. Standardized protocols were used for the active stand procedure; however, it was not possible to control for factors such as last meal, smoking, and time of medication administration. Baseline OH as measured at wave 1 health center assessment using the finometer was used.BP was also measured seated, using the traditional oscillometric methods. Two seated SBP and DBP measurements were obtained, separated by 1 minute, using an automatic digital BP monitor (Model M10‐IT; OMRON, Kyoto, Japan). Seated hypertension was assessed using oscillometric BP. Hypertension was defined as a systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg.

Cognitive Assessment {#jah33505-sec-0012}
--------------------

Global cognitive function was assessed using the MOCA. The MOCA is a cognitive test including assessment of the cognitive domains of executive and visuospatial function, memory, language, and attention; the test yields a single score ranging from 0 to 30. MOCA was administered at the health center. The MOCA is used frequently in the clinical setting,[25](#jah33505-bib-0025){ref-type="ref"} is sensitive to mild deficits, and is useful in identifying patients with mild cognitive impairment.[26](#jah33505-bib-0026){ref-type="ref"} In addition to this, it demonstrates good test--retest and interrater reliability.[27](#jah33505-bib-0027){ref-type="ref"} The MOCA was assessed as a total score to assess global cognition (maximum score 30). The results of MOCA were then divided into subdomains and assessed individually, including recall, visuospatial, executive function, attention, and working memory, language, and orientation. To assess recall, the delayed recall section of the MOCA was used (maximum score 5). To assess the visuospatial domain, cube drawing and clock drawing were used (maximum score 4). Executive function was assessed using the trail test within the MOCA, language fluency and a 2‐item verbal abstraction task (maximum score 4). Attention and working memory was assessed using digits forward and backward, a sustained attention task, and serial subtraction task (maximum score 6). Language was assessed using animal naming, repetition, and the language fluency task (maximum score 6). Finally, orientation to time and place was assessed using questions regarding date, month, year, day, place, and city were used (maximum score 6).

Baseline results of MOCA from wave 1 and follow‐up MOCA scores at wave 3 were used.

Covariates {#jah33505-sec-0013}
----------

Results were adjusted for variables that have a known association with OH and cognitive decline. Information on age, sex, education attainment, smoking status, and alcohol use (using the CAGE questionnaire[28](#jah33505-bib-0028){ref-type="ref"}) was collected during the CAPI. The CAPI also collected information on self‐reported comorbidities including self‐reported hypertension, heart failure, angina, myocardial infarction, diabetes mellitus, stroke, transient ischemic attack, murmur, atrial fibrillation, or other arrhythmia. Mean of 2 seated BP measurements was used to assess as objective BP measurements. In wave 1, depressive symptoms were assessed using the Centre for Epidemiological Studies Depression scale.[29](#jah33505-bib-0029){ref-type="ref"} A cut‐off score of 16 was used to assess the presence of depression. In wave 3, a short form of the Centre for Epidemiological Studies Depression scale was used,[30](#jah33505-bib-0030){ref-type="ref"} with a cut‐off score of 10 used to assess the presence of depression. Height and baseline BP were measured at the health assessment. Frailty was assessed using the Fried Frailty scale,[31](#jah33505-bib-0031){ref-type="ref"} and individuals were grouped in 3 groups---not frail, pre‐frail, or frail.

All medications were recorded at the CAPI and classified according to the Anatomical therapeutic classification codes. Medication categories adjusted for were antihypertensive agents ("CO2"), diuretics ("C03"), β‐blockers ("C07"), calcium channel blockers ("C08"), angiotensin converting enzyme inhibitors ("C09"), antipsychotic ("N05A"), antidepressants ("N06A"), anxiolytics ("N05B"), hypnotics and sedatives ("N05C"), anticholinergic agents ("N04A"), anticholinesterases ("N06DA"), and diabetic medication ("A10").

Statistical Analysis {#jah33505-sec-0014}
--------------------

All statistical analyses were carried out using STATA 14 (Stata Corporation). For description of data, normally distributed continuous variables were compared using *t* tests; nonnormally distributed continuous variables were compared using Mann--Whitney tests and categorical variables were compared using χ^2^ tests. Q‐Q plots were used to assess normality.

MOCA scores showed a left‐skewed distribution at waves 1 and 3. Therefore, we calculated the number of errors on MOCA at each wave (ie, 30 minus MOCA score), and modeled the change in participants' MOCA error rates between waves using mixed effects Poisson models. Interactions with a variable representing wave (wave 1---baseline assessment; wave 3---assessment at 4‐year follow‐up interval) for each predictor variable were included to probe change in number of errors on the MOCA (presented as incident rate ratio \[IRR\]). Wave was also included as a fixed effect predictor in the model. For analysis of subdomains in MOCA, the number of errors was calculated by subtracting the score obtained for that domain from the maximum score possible for the domain. Separate models were fitted to assess the impact of OH40 and OH110 on MOCA. All models treated participant as a random effect, with random intercept (ie, MOCA errors at wave 1 and wave 3 were nested participant‐wise). Three models were fitted for OH40 and for OH110; model A, with fixed effect of OH only; model B, a multivariable model controlling for fixed effects of age, sex, and education; and model C, a multivariable model controlling for fixed effects of age, sex, education, self‐reported hypertension, self‐reported heart failure, number of cardiovascular conditions, diabetes mellitus, alcohol use, smoking status, depression, height, frailty, baseline SBP, pulse pressure, heart rate before stand (wave 1), and medication use (grouped as antihypertensive use, antidepressant use, antipsychotic use, and anticholinesterase, anticholinergic or sedative use, and antidiabetic use). Covariates were chosen based on clinical relevance and current literature. Variables were assessed for multicollinearity using variance inflation factors with a cut‐off score of 10, with the exception of interactions and the fixed effect for wave. Information on available covariates from both waves was included in the fully adjusted model, and an interaction with the variable representing wave was included.

Models were then repeated testing the interaction between OH and the presence or absence of hypertension; this was assessed by including a 3‐way interaction term between the variable representing wave, OH, and hypertension. All models were then repeated including only age group 50 to 64 years and including only age group ≥65 years, both with and without inclusion of a 3‐way interaction with wave, OH, and hypertension. This was to assess the impact of the presence of hypertension as well as to assess how the results differ in the younger and older age groups.

Results {#jah33505-sec-0015}
=======

In total, 8175 participants over the age of 50 years were recruited to wave 1 of the TILDA study, of whom 5035 attended the health center for assessment at wave 1. There were 4475 participants ≥50 years of age with adequate active stand data for analysis, of whom 4172 fulfilled inclusion criteria. Of these individuals, 3338 were present at the wave 3 health center for assessment and did not receive a diagnosis of Parkinson\'s disease or stroke between waves 1 and 3, and were included in the study. Figure [1](#jah33505-fig-0001){ref-type="fig"} details a flow chart of participants included for analysis. Characteristics of participants who were included in the baseline sample but did not have a follow‐up MOCA and therefore were not included in the final sample are provided in Table [1](#jah33505-tbl-0001){ref-type="table"}. Participants who did not have a follow‐up MOCA assessment were older, with lower MOCA scores and higher prevalence of OH.

![Sample for analysis. MOCA indicates Montreal Cognitive Assessment; OH110, orthostatic hypotension sustained up to 110 seconds post stand; OH40, orthostatic hypotension sustained up to 40 seconds post stand; PD, Parkinson\'s disease.](JAH3-7-e008976-g001){#jah33505-fig-0001}

###### 

Description of Attrition

                                               No Follow‐up MOCA (N=794)                             Analytic Sample (N=3338)
  -------------------------------------------- ----------------------------------------------------- --------------------------
  Age, mean±SD                                 61.9±8.7[a](#jah33505-note-0003){ref-type="fn"}       61.1±8.0
  MOCA, mean±SD                                25.0±2.7[b](#jah33505-note-0005){ref-type="fn"}       25.9±2.5
  OH40, % (n)                                  12.5% (99)[a](#jah33505-note-0003){ref-type="fn"}     9.5% (316)
  OH110, % (n)                                 4.9 (39)                                              4.2% (141)
  Female, % (n)                                54.3% (431)                                           54.2% (1808)
  Education, % (n)                                                                                   
  Primary                                      24.1% (191)[b](#jah33505-note-0005){ref-type="fn"}    17.4% (581)
  Secondary                                    44.2% (352)[b](#jah33505-note-0005){ref-type="fn"}    42.3% (1411)
  Higher                                       31.5% (250)[b](#jah33505-note-0005){ref-type="fn"}    40.3% (1347)
  Smoking status, % (n)                                                                              
  Current                                      20.15% (160)[b](#jah33505-note-0005){ref-type="fn"}   13.6% (454)
  CVD disease prevalence, % (n)                                                                      
  ≥2 cardiovascular diseases                   12.3% (98)                                            11.9% (396)
  Seated systolic BP, mean±SD                  131.6±21.6[a](#jah33505-note-0003){ref-type="fn"}     129.8±20.3
  Seated diastolic BP, mean±SD                 68.6±10.8                                             68.0±10.7
  Taking antihypertensive medications, % (n)   12.3% (98)                                            11.9% (396)
  Taking antidepressant medications, % (n)     6.7% (53)                                             5.2% (174)
  Frailty, % (n)                                                                                     
  Pre frail/frail                              30.8% (237)[b](#jah33505-note-0005){ref-type="fn"}    24.1% (789)

BP indicates blood pressure; CVD, cardiovascular disease; MOCA, Montreal Cognitive Assessment; OH110, orthostatic hypotension sustained to 110 seconds post stand; OH40, Orthostatic hypotension sustained to 40 seconds post stand.

*P*\<0.05.

*P*\<0.01.

*P*\<0.001.

Population characteristics are described in Table [2](#jah33505-tbl-0002){ref-type="table"}. OH40 was present in 9.46% of participants, and OH110 was present in 4.22% of participants included for analyses. Individuals with OH40 and OH110 on active stand were older, showed lower levels of education, had higher systolic BP, lower baseline heart rate, and higher burden of cardiovascular disease. They were more likely to be taking both antihypertensive and antidepressant medications. Those with OH40 also had higher levels of frailty.

###### 

Population Characteristics by Presence of OH

  Characteristics                              OH40 (n=316)                                         OH110 (n=141)                                       No OH (n=3023)
  -------------------------------------------- ---------------------------------------------------- --------------------------------------------------- ----------------
  Age, mean±SD                                 66.1±8.7[a](#jah33505-note-0007){ref-type="fn"}      65.3±8.3[a](#jah33505-note-0007){ref-type="fn"}     60.7±7.7
  Female, % (n)                                60.3% (193)[b](#jah33505-note-0008){ref-type="fn"}   66.9% (95)[c](#jah33505-note-0009){ref-type="fn"}   53.2% (1623)
  Education, % (n)                                                                                                                                      
  Primary                                      23.8% (76)[b](#jah33505-note-0008){ref-type="fn"}    23.9% (34)[b](#jah33505-note-0008){ref-type="fn"}   16.9% (517)
  Secondary                                    39.1% (125)[b](#jah33505-note-0008){ref-type="fn"}   45.1% (64)[b](#jah33505-note-0008){ref-type="fn"}   42.5% (1297)
  Third/higher                                 37.2% (119)[b](#jah33505-note-0008){ref-type="fn"}   30.2% (44)[b](#jah33505-note-0008){ref-type="fn"}   40.6% (1239)
  Smoking status, % (n)                                                                                                                                 
  Never                                        45.6% (146)                                          47.9% (68)                                          47.3% (1443)
  Past                                         40.0% (128)                                          34.5% (49)                                          39.1% (1194)
  Current                                      14.4% (46)                                           17.6% (25)                                          13.6% (416)
  Alcohol (CAGE)                                                                                                                                        
  0                                            75.9% (230)                                          75.7% (100)                                         75.6% (2048)
  1                                            10.9% (33)                                           10.6% (14)                                          12.6% (355)
  2                                            8.3% (25)                                            4.6% (6)                                            9.5% (268)
  3                                            1.0% (3)                                             1.0% (3)                                            0.7% (19)
  Height, mean±SD                              165.1±9.0[b](#jah33505-note-0008){ref-type="fn"}     164.1±9.2[a](#jah33505-note-0007){ref-type="fn"}    166.7±9.1
  MOCA, mean±SD                                25.6±2.6[b](#jah33505-note-0008){ref-type="fn"}      25.8±2.6                                            26.0±2.5
  Self‐reported hypertension, % (n)            38.8% (124)[c](#jah33505-note-0009){ref-type="fn"}   40.9% (58)[b](#jah33505-note-0008){ref-type="fn"}   30.9% (944)
  Self‐reported heart failure, % (n)           0.6% (2)                                             n=0                                                 0.8% (25)
  Self‐reported diabetes mellitus, % (n)       6.9% (22)                                            7.8% (11)                                           6.0% (183)
  Disease prevalence, % (n)                                                                                                                             
  ≥2 CVDs                                      16.9% (54)[a](#jah33505-note-0007){ref-type="fn"}    14.8 (20)[b](#jah33505-note-0008){ref-type="fn"}    11.6% (355)
  Seated systolic BP, mean±SD                  136.9±23.8[a](#jah33505-note-0007){ref-type="fn"}    140.3±23.2[a](#jah33505-note-0007){ref-type="fn"}   129.1±19.8
  Seated diastolic BP, mean±SD                 67.8±11.1[a](#jah33505-note-0007){ref-type="fn"}     70.6±11.5[c](#jah33505-note-0009){ref-type="fn"}    70.1±11.1
  Taking antihypertensive medications, % (n)   39.1% (125)[a](#jah33505-note-0007){ref-type="fn"}   39.4% (56)[c](#jah33505-note-0009){ref-type="fn"}   29.8% (909)
  Taking antidepressant medications, % (n)     8.8% (28)[b](#jah33505-note-0008){ref-type="fn"}     9.2% (13)[b](#jah33505-note-0008){ref-type="fn"}    4.9% (148)
  Taking antipsychotic medications, % (n)      1.3% (4)                                             0.7% (1)                                            0.9% (28)
  Taking antidiabetic medication, % (n)        5.3% (17)                                            6.3% (9)                                            4.3% (132)
  Frailty, % (n)                                                                                                                                        
  Pre‐frail/frail                              31.2% (97)[c](#jah33505-note-0009){ref-type="fn"}    28.1% (39)                                          23.5% (706)
  CES‐D score, mean±SD                         4.8±5.8                                              4.3±4.8                                             5.2±6.5
  Baseline HR, mean±SD                         62.5±10.1%[a](#jah33505-note-0007){ref-type="fn"}    61.8±934[a](#jah33505-note-0007){ref-type="fn"}     65.2±9.8

BP indicates blood pressure; CAGE, CAGE Questionnaire; CES‐D, Centre for Epidemiological Studies Depression; HR, heart rate; MOCA, Montreal Cognitive Assessment; OH, orthostatic hypotension; OH110, OH up to 110 seconds; OH40, OH up to 40 seconds.

*P*\<0.001.

*P*\<0.05.

*P*\<0.01.

The change between waves in number of errors on MOCA in individuals with OH40 is described in Table [3](#jah33505-tbl-0003){ref-type="table"}, with change in rates of errors presented as IRR. Participants with OH40 at baseline had an increase in rates of errors over the 4 years in model A (IRR 1.12, 95% confidence interval \[CI\], 1.04--1.21, *P=*0.004); however, this was no longer significant when controlling for age, sex, and level of education (IRR 1.05, 95% CI, 0.97--1.15, *P*=0.205), or on controlling for all covariates (IRR 1.09, 95% CI, 0.99--1.20, *P*=0.067). Results of the full multivariable analysis are provided in Table [S1](#jah33505-sup-0001){ref-type="supplementary-material"}. There was no significant increase in rates of errors in MOCA between the 2 waves including only participants in the age group 50 to 64 years, or including only participants in the age group ≥65 years (Table [3](#jah33505-tbl-0003){ref-type="table"}).

###### 

Change in Global Cognition Between Waves for All Ages Based on Baseline OH40 and OH110

                           OH40                OH110                                                              
  ------------------------ ------------------- ---------------------------------------------- ------------------- ----------------------------------------------
  Full cohort, N=3338                                                                                             
  Model A                  1.12 (1.04, 1.21)   0.004[a](#jah33505-note-0011){ref-type="fn"}   1.17 (1.04, 1.31)   0.007[a](#jah33505-note-0011){ref-type="fn"}
  Model B                  1.05 (0.97, 1.14)   0.205                                          1.11 (0.99, 1.25)   0.065[a](#jah33505-note-0011){ref-type="fn"}
  Model C                  1.09 (0.99, 1.20)   0.067                                          1.17 (1.02, 1.33)   0.028[a](#jah33505-note-0011){ref-type="fn"}
  Age 50 to 64 y, N=2267                                                                                          
  Model A                  1.09 (0.96, 1.24)   0.170                                          1.22 (1.01, 1.47)   0.038[a](#jah33505-note-0011){ref-type="fn"}
  Model B                  1.09 (0.96, 1.24)   0.197                                          1.22 (1.02, 1.48)   0.034[a](#jah33505-note-0011){ref-type="fn"}
  Model C                  1.13 (0.98, 1.31)   0.104                                          1.25 (1.01, 1.57)   0.048[a](#jah33505-note-0011){ref-type="fn"}
  Age ≥65 y, N=1071                                                                                               
  Model A                  1.05 (0.95, 1.17)   0.306                                          1.06 (0.92, 1.22)   0.441
  Model B                  1.02 (0.92, 1.13)   0.688                                          1.05 (0.90, 1.21)   0.549
  Model C                  1.05 (0.92, 1.19)   0.459                                          1.09 (0.91, 1.30)   0.370

Model A---Univariate; Model B---Controls for age, sex, and education; Model C---Controls for all covariates---age, sex, education level, self‐reported cardiovascular conditions, diabetes mellitus, alcohol use, smoking status, medications, depression, frailty, mean blood pressure, pulse pressure height, and baseline heart rate. CI indicates confidence interval; IRR, incidence rate ratio; OH110, orthostatic hypotension sustained to 110 seconds; OH40, orthostatic hypotension sustained to 40 seconds.

Statistically significant *P* values.

The change between waves in rates of errors in MOCA in individuals with OH110 compared with those without OH110 is also described in Table [3](#jah33505-tbl-0003){ref-type="table"}. Participants with OH110 had an increase in number of errors in MOCA compared with those without OH110 on univariate analysis (IRR 1.17, 95% CI, 1.04--1.31, *P*=0.007); this remained significant on controlling for all covariates (1.17, 95% CI, 1.02--1.33, *P*=0.028). Results of the full multivariable analysis for the full age cohort are provided in Table [S2](#jah33505-sup-0001){ref-type="supplementary-material"}. The analysis was then repeated including only age group 50 to 64 years and including only age group ≥65 years, and results are also presented in Table [3](#jah33505-tbl-0003){ref-type="table"}. In the age group 50 to 64 years, individuals with OH110 had an increase in rates of errors on the MOCA between waves, compared with those without OH on univariate analysis (IRR 1.22, 95% CI, 1.01--1.47, *P*=0.038), which remained significant on controlling for all confounders (IRR 1.25, 95% CI, 1.01--1.57, *P*=0.048). In the age group ≥65 years there was no significant increase in rates of errors on MOCA in those with OH110 compared with those without OH110 between waves (Table [3](#jah33505-tbl-0003){ref-type="table"}). The results of the full multivariable models for age group 50 to 64 years are presented in Tables [S3](#jah33505-sup-0001){ref-type="supplementary-material"} and [S4](#jah33505-sup-0001){ref-type="supplementary-material"}. The results of the full multivariable models for age group ≥65 years are presented in Tables [S5](#jah33505-sup-0001){ref-type="supplementary-material"} and [S6](#jah33505-sup-0001){ref-type="supplementary-material"}. The decrease in absolute MOCA scores in those with OH110 compared with those without OH110 is small (0.65 points on MOCA); however, there is a clear divergence between the 2 groups seen in the results (Figure [2](#jah33505-fig-0002){ref-type="fig"}).

![MOCA at wave 1 and wave 3 with 95% CI by presence of OH110 at wave 1. CI indicates confidence interval; MOCA, Montreal Cognitive Assessment; OH110, orthostatic hypotension sustained to 110 seconds.](JAH3-7-e008976-g002){#jah33505-fig-0002}

All analyses were then repeated testing for the interaction with the presence of hypertension at baseline in the full age cohort, in the age group 50 to 64 years and in the age group ≥65 years. These results are presented in Table [4](#jah33505-tbl-0004){ref-type="table"}. In the full age cohort, individuals with both OH40 and hypertension were more likely to show an increased rate of MOCA errors over the 4‐year follow‐up period, which was significant on controlling for all confounders (IRR 1.18, 95% CI, 1.03--1.34, *P*=0.017). Individuals with OH40 alone or hypertension alone were no more likely to show a difference in error rate than those without OH40 or hypertension on controlling for confounders (Table [4](#jah33505-tbl-0004){ref-type="table"}). In the age group 50 to 64 years, participants with OH40 and hypertension at baseline had an increase in the rates of errors on MOCA, which was significant on controlling for all confounders (IRR 1.29, 95% CI, 1.03--1.62, *P*=0.025). Again, those with OH40 alone or hypertension alone were no more likely to show an increase in rates of errors compared with those with no OH40 and no hypertension (Table [4](#jah33505-tbl-0004){ref-type="table"}). Results of the full multivariable analysis for OH40 in the full cohort are presented in Table [S7](#jah33505-sup-0001){ref-type="supplementary-material"}.

###### 

Change in Global Cognition Between Waves Based on Baseline OH and Stratified by Baseline HTN

                                 OH40                OH110                                                                
  ------------------------------ ------------------- ------------------------------------------------ ------------------- ----------------------------------------------
  Full cohort, N=3338                                                                                                     
  Model A (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.09 (1.01, 1.12)   0.013[a](#jah33505-note-0013){ref-type="fn"}     1.07 (1.02, 1.13)   0.006[a](#jah33505-note-0013){ref-type="fn"}
  OH, No HTN                     1.08 (0.94, 1.23)   0.262                                            1.12 (0.92, 1.37)   0.264
  OH and HTN                     1.19 (1.09, 1.32)   \<0.001[a](#jah33505-note-0013){ref-type="fn"}   1.25 (1.09, 1.44)   0.001[a](#jah33505-note-0013){ref-type="fn"}
  Model B (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.03 (0.97, 1.08)   0.326                                            1.03 (0.98, 1.08)   0.241
  OH, No HTN                     1.01 (0.88, 1.15)   0.907                                            1.08 (0.89, 1.32)   0.438
  OH and HTN                     1.10 (0.99, 1.22)   0.06                                             1.16 (1.01, 1.33)   0.042[a](#jah33505-note-0013){ref-type="fn"}
  Model C (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.03 (0.95, 1.11)   0.478                                            1.04 (0.96, 1.13)   0.365
  OH, No HTN                     1.00 (0.86, 1.17)   0.976                                            1.07 (0.84, 1.35)   0.594
  OH and HTN                     1.18 (1.03, 1.34)   0.017[a](#jah33505-note-0013){ref-type="fn"}     1.27 (1.06, 1.53)   0.011[a](#jah33505-note-0013){ref-type="fn"}
  Age 50--64 y, N=2267                                                                                                    
  Model A (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.03 (0.97, 1.10)   0.330                                            1.04 (0.97, 1.10)   0.265
  OH, No HTN                     1.00 (0.83, 1.21)   0.982                                            1.08 (0.83, 1.41)   0.562
  OH and HTN                     1.20 (1.01, 1.42)   0.036[a](#jah33505-note-0013){ref-type="fn"}     1.42 (1.09, 1.85)   0.010[a](#jah33505-note-0013){ref-type="fn"}
  Model B (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.03 (0.96, 1.10)   0.394                                            1.03 (0.97, 1.10)   0.314
  OH, No HTN                     0.98 (0.82, 1.20)   0.909                                            1.08 (0.82, 1.41)   0.577
  OH and HTN                     1.20 (1.01, 1.43)   0.035[a](#jah33505-note-0013){ref-type="fn"}     1.43 (1.10, 1.87)   0.008[a](#jah33505-note-0013){ref-type="fn"}
  Model C (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.00 (0.91, 1.11)   0.940                                            1.01 (0.91, 1.13)   0.762
  OH, No HTN                     1.01 (0.82, 1.24)   0.932                                            1.07 (0.79, 1.45)   0.670
  OH and HTN                     1.29 (1.03, 1.62)   0.025[a](#jah33505-note-0013){ref-type="fn"}     1.52 (1.08, 2.15)   0.017[a](#jah33505-note-0013){ref-type="fn"}
  Age ≥65 y, N=1071                                                                                                       
  Model A (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.05 (0.96, 1.14)   0.302                                            1.05 (0.96, 1.14)   0.269
  OH, No HTN                     1.07 (0.89, 1.29)   0.484                                            1.11 (0.82, 1.50)   0.518
  OH and HTN                     1.09 (0.96, 1.24)   0.187                                            1.08 (0.92, 1.28)   0.346
  Model B (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.03 (0.94, 1.12)   0.573                                            1.03 (0.95, 1.12)   0.517
  OH, No HTN                     1.02 (0.84, 1.24)   0.837                                            1.09 (0.81, 1.48)   0.577
  OH and HTN                     1.04 (0.92, 1.19)   0.511                                            1.06 (0.89, 1.25)   0.529
  Model C (base No OH, no HTN)                                                                                            
  No OH, HTN                     1.09 (0.96, 1.25)   0.160                                            1.09 (0.97, 1.24)   0.148
  OH, No HTN                     1.05 (0.82, 1.34)   0.690                                            1.07 (0.73, 1.57)   0.716
  OH and HTN                     1.15 (0.96, 1.34)   0.126                                            1.19 (0.95, 1.50)   0.123

Results of comparison to base of No OH and no HTN. Model A---Univariate; Model B---Controls for age, sex, and education; Model C---Controls for all covariates. CI indicates confidence interval; HTN, hypertension; IRR, incidence rate ratio; OH110, orthostatic hypotension sustained to 110 seconds; OH40, orthostatic hypotension sustained to 40 seconds.

Statistically significant *P* values.

Participants with OH110 and hypertension also showed an increase in rates of errors in MOCA between the time points, compared with those with no OH110 and no hypertension, which was significant on controlling for all confounders (IRR 1.27, 95% CI, 1.06--1.53, *P*=0.011). Results of the full multivariable analysis are presented in Table [S8](#jah33505-sup-0001){ref-type="supplementary-material"}. Repeating the analysis including only those in the 50 to 64 year age group at baseline showed similar results, with those with both OH110 and hypertension showing an increase in the rates of errors on the MOCA (IRR 1.52, 95% CI, 1.08--2.15, *P*=0.017) compared with reference (no OH, no hypertension). Again there was no significant increase in rates of errors in those with OH110 alone or those with hypertension alone, nor was there any significant increase in those aged ≥65 years (Table [4](#jah33505-tbl-0004){ref-type="table"}).

When analyzing the results of individual subdomains assessed by MOCA, there is an increase in the rate of errors in the domain of executive function in those with OH40 (IRR 1.32; 95% CI, 1.11, 1.57; *P*=0.002), which remains significant on controlling for all confounders (IRR 1.27; 95% CI, 1.03, 1.56; *P*=0.027). Those with OH110 also showed an increase in the rate of errors made in the domain of executive function (IRR 1.53; 95% CI, 1.18, 1.99; *P*=0.002), and again this remained significant on controlling for all confounders (IRR 1.40; 95% CI, 1.03, 1.94; *P*=0.032). There was no significant increase in error rates seen in the other subdomains assessed by MOCA.

Discussion {#jah33505-sec-0016}
==========

Adults with OH are more likely to show an increase in rate of MOCA errors at 4‐year follow‐up, which remains significant following adjustment for confounders. The association is strongest in participants who fail to recover blood pressure throughout the 110‐seconds stand. There is evidence that cerebral perfusion is impaired in OH,[13](#jah33505-bib-0013){ref-type="ref"}, [14](#jah33505-bib-0014){ref-type="ref"} and we hypothesize that those individuals who fail to recover their BP throughout the 110 seconds stand at baseline are therefore exposed to the highest "load" of cerebral hypoperfusion. This association may reflect periods of cerebral hypoperfusion. The association appears to be dependent on the presence of coexistent hypertension, and on age. Individuals with both OH (OH40, OH110) and hypertension showed an increase in rates of errors on MOCA between waves, but this was true only in those aged \<65 years. On analysis of the domains assessed by the MOCA individually, it is the domain of executive dysfunction within the MOCA that appears to drive this increase in errors on MOCA. Hypoperfusion of the prefrontal cortex has been reported in OH compared with controls,[32](#jah33505-bib-0032){ref-type="ref"} which may explain these results because executive function is largely controlled by the prefrontal cortex.

The relationship between BP and cognitive function is complex, with both high and low BP being linked with cognitive decline and dementia.[33](#jah33505-bib-0033){ref-type="ref"} A nonlinear, U‐shaped relationship between BP and cognitive function has been proposed, with individuals with both high and low BP performing worse on cognitive tests than individuals with BP in the midrange.[34](#jah33505-bib-0034){ref-type="ref"} Hypertension has been consistently linked with cognitive impairment and dementia, particularly midlife hypertension.[33](#jah33505-bib-0033){ref-type="ref"} It is postulated that microvascular dysfunction and damage induced by hypertension leads to white matter disease, microinfarcts, and microhemorrhages, which are correlated with cognitive dysfunction.[35](#jah33505-bib-0035){ref-type="ref"} Several mechanisms are proposed to explain the association between cognitive decline and OH. Cerebral autoregulation may be attenuated with aging, with subsequent failure to adapt to repeated oscillations in BP.[36](#jah33505-bib-0036){ref-type="ref"} This may result in impaired cerebral perfusion and cell damage.[14](#jah33505-bib-0014){ref-type="ref"}, [37](#jah33505-bib-0037){ref-type="ref"} Enhanced white matter hyperdensities are evident in such circumstances,[18](#jah33505-bib-0018){ref-type="ref"} and increasing white matter lesion burden is associated with an increased risk of dementia and also predicts an increased risk of cognitive decline in mild cognitive impairment.[5](#jah33505-bib-0005){ref-type="ref"}

In the current study, individuals with both OH and hypertension exhibited a higher rate of decline in cognitive test scores, whereas individuals with isolated OH or isolated hypertension did not show a decline. Both hypertension[38](#jah33505-bib-0038){ref-type="ref"} and OH[39](#jah33505-bib-0039){ref-type="ref"} are associated with impaired baroreflex, and coexistent OH and hypertension represents a more severe baroreflex dysfunction and exaggerated BP variability. Hypertension causes alterations in the structure and function of cerebral arteries, with loss of elasticity and compliance, resulting in increased myogenic tone, affecting cerebral autoregulation.[5](#jah33505-bib-0005){ref-type="ref"} Thus, hypertension coupled with OH leads to greater BP variability as well as a diminished ability to protect against periods of hypotension when SBP falls below a critical threshold.

These findings are in line with a number of recent longitudinal studies that have found an increase in the rate of incident dementia based on baseline OH, including the Rotterdam Study,[40](#jah33505-bib-0040){ref-type="ref"} the Malmo Preventative Project,[41](#jah33505-bib-0041){ref-type="ref"} and the Three‐City Study.[42](#jah33505-bib-0042){ref-type="ref"} The follow‐up period for these studies is longer (12--28 years) than in the current study. All assessed incident dementia rather than change in global cognitive test scores such as MOCA. The baseline age ranges were 68.5±8.6 years in the Rotterdam Study, 45±7 and 50±5 years in the Dementia‐negative and Dementia‐positive groups, respectively, in the Malmo Preventative Project, and 74±5 in the Three‐City Cohort. It is not reported that younger individuals within these groups showed a stronger association with dementia. In all 3 studies OH was assessed using traditional oscillometric methods. Phenotypes of OH as defined in the current study (OH40 and OH110) were not assessed, and therefore it is not possible to elicit whether individuals with a higher "load" of cerebral hypoperfusion (ie, OH110 in the current study) were more likely to develop dementia. However, in the Three‐City Study, they assessed the traditional thresholds for OH, as well as assessing increasing levels of severity, based on the size of the BP drop, and found that there was a stronger association with the severe OH group. Similarly, in the Rotterdam study, OH was characterized into 3 groups of increasing "severity" of OH; however, in this study they did not observe that increasing severity of OH influenced the association with dementia, possibly because individuals with more severe OH have higher morbidity and mortality.[43](#jah33505-bib-0043){ref-type="ref"} In the Malmo Preventative Study, postural changes in SBP and DBP were assessed as well as the presence of OH as defined traditionally, and found the association between postural DBP changes and dementia was strongest. These studies did not report that the association between OH and dementia was dependent on coexistent hypertension.

The increased rates of errors on MOCA are most robustly observed in the younger age group in our sample (age 50--64 years). This is consistent with studies on hypertension, where midlife hypertension is consistently linked with cognitive impairment. The picture is more complex in older adults, where the association between late‐life measures of BP and cognition are less consistent.[44](#jah33505-bib-0044){ref-type="ref"} Whether OH could represent an early, modifiable risk factor for cognitive impairment and dementia requires further exportation given these observational data. However, the management of supine hypertension coupled with OH is complicated because pharmacological interventions for OH exacerbate supine hypertension.[45](#jah33505-bib-0045){ref-type="ref"} Management using conservative measures such as fluid hydration, physical counter maneuvers, and compression hosiery may provide a nonpharmacological alternative.[46](#jah33505-bib-0046){ref-type="ref"}, [47](#jah33505-bib-0047){ref-type="ref"} Supine hypertension and OH often coexist,[46](#jah33505-bib-0046){ref-type="ref"} and hypertension can lead to alteration of cerebral autoregulation capacity, the process of maintaining stable cerebral perfusion despite variation in peripheral blood pressure,[12](#jah33505-bib-0012){ref-type="ref"} further exposing individuals with hypertension to ischemia and hypoxia when systemic BP drops.[48](#jah33505-bib-0048){ref-type="ref"}

There are some limitations to the current study. The follow‐up period is relatively short for assessing decline in global cognition. Cardiovascular confounders that were controlled for relied on self‐reported conditions, and exclusion based on a doctor\'s diagnosis of dementia also relied on self‐reporting. The population included in the study was a predominantly white population. The MOCA was used to assess cognition as it is commonly used in clinical practice; however, it is not specifically designed to assess longitudinal changes in cognition. The principal strength of the current study is its use of beat‐to‐beat measurement of BP response to stand using a finometer, which allows a precise assessment of BP behavior in response to orthostasis and can detect more subtle fluctuations in BP. TILDA allows inclusion of a large number of confounders, including both self‐reported and objective measures. It is noteworthy that individuals without OH110 showed a slight improvement in their MOCA scores, which may reflect in a practice effect.[49](#jah33505-bib-0049){ref-type="ref"} In contrast, cognition declined in those with OH, indicating the potential detrimental effect of BP variability.

In conclusion, we found that OH is associated with a decline in global cognition over a 4‐year follow‐up period in a community‐dwelling population over the age of 50 years. This association appears to be dependent on the presence of coexistent hypertension and is strongest in the middle‐aged group. Follow‐up at future waves of the TILDA data set will allow assessment of the impact of BP behavior on the rate of cognitive decline and rate of incident dementia in these individuals.
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